Celebrating the U.S. Debut of NEST Pen Injectors!-무석내사생명과학기술주식유한회사

Riding the waves of success and soaring to new height, as a New Jersey-based company with over a decade of experience, we are committed to meeting diverse customer needs while continuously expanding NEST's product line in the life sciences sector and strengthening our global supply chain.

On September 2 1 , we held a grand ceremony to mark the first shipment of NEST pen injectors produced at our , facility to our U.S. headquarters.

At the launch event, a truck carrying NEST pen injectors was ready to depart, representing over ten years of hard work and a hopeful vision for future growth.

Live from the scene:

NEST obtained its medical device production license in 2021 and has since developed a product line that includes disposable pen injector components, SP pen injector components, single-dose disposable injector pens, reusable pen injectors, and prefilled pen injectors. These products are compatible with medications such as semaglutide, follicle-stimulating hormone (FSH), liraglutide, insulin, and growth hormones.

In recent years, the global pharmaceutical packaging industry has seen rapid growth, and this momentum continues. From R&D to production and commercialization, NEST is accelerating its efforts to contribute to the international life sciences market.

Both NEST ' s disposable and reusable pen injectors have successfully obtained U.S. FDA 510(k) certification!

The first entry of NEST ' s pen injectors into the U.S. market is not only a testament to the quality of our products but also a significant step forward in advancing NEST's international strategy and global presence.

Although pen injectors simplify drug administration, the technology behind the pens involves significant technical barriers. From tool design to injection molding and assembly, there are more than 40,000 patents covering these processes, with over 1,500 patents on core structures alone. The vast majority of these are controlled by around ten multinational giants.

For years, NEST has invested significant time and effort in R&D, focusing on transforming technological breakthroughs and overcoming industry bottlenecks and breaking through patent barriers. Currently, both NEST's disposable and reusable pen injectors have passed Freedom to Operate (FTO) reviews in both and the U.S., ensuring there is no risk of patent infringement .

Since its founding, research and innovation have been integral to NEST ’ s brand DNA. By continually driving innovation, NEST enhances its competitive edge in the market.

Today marks a new milestone for NEST in the pharmaceutical packaging materials sector. We will continue investing in R&D and strengthening our business chain, steadily growing into a comprehensive service provider in the multi-disciplinary life sciences industry!

반환목록

이전：NEST Tube is adopted by WHO, Uganda to test Ebola Vaccines in outbreak 2022-11-24

다음：The Rise of Organoid Culture: FDA Approval Paves the Way for Innovative Alternatives to Animal Testing 2024-11-11